Randomised trials: substudies and extended follow-up - A quick update

Anchorperson: P. Lemos

Spokesperson: V. Paradies

Summary

This session provides a quick update on various randomised trials, including substudies and extended follow-up data. It covers insights on bifurcation stenting, the symptom-stratified analysis of ORBITA-2, the impact of completeness of revascularisation on clinical outcomes from REVIVED-BCIS2, cost-effectiveness of CABG vs. PCI from FAME 3, long-term outcomes of hybrid coronary revascularisation, and improved DES for left main PCI from the IDEAL-LM Trial.

Presentations available when logged in:

Keep bIfurcation Single stenting Simple
ORBITA2-Symptoms: the symptom-stratified analysis of ORBITA-2
Does completeness of revascularisation affect clinical outcomes? Insights from REVIVED-BCIS2
Is coronary artery bypass surgery cost-effective compared with contemporary PCI? A FAME 3 analysis
Hybrid coronary revascularisation–10-year clinical outcomes of the prospective randomised study.
Long-term outcomes after immediate versus staged complete revascularisation in STEMI or NSTE-ACS
Improved DES for left main PCI in an all-comers population: 5-year results of the IDEAL-LM Trial